|  | COVID-19 clinical operations
ICON has adopted numerous measures to protect the welfare of patients, to protect the safety of our employees and to ensure the continuity of your research programmes during COVID-19. Learn more about how to keep your trial on track in this evolving environment.
|
Today's Rundown Featured Story | | | Thursday, May 14, 2020 With all eyes on the prize for a COVID-19 vaccine, researchers are setting aggressive timetables that might be too good to be true. Despite hopes that a shot could be available this year, Novartis' CEO is pumping the brakes—and given his past vaccines experience, he should know. |
|
|---|
|
Top Stories Thursday, May 14, 2020 Amid widespread speculation on COVID-19 vaccine timelines, former BARDA chief turned whistleblower Rick Bright said he's skeptical vaccines can be made available in 12 to 18 months. That would require R&D to go “perfectly” from the very start, and “we’ve never seen everything go perfectly," he said. Thursday, May 14, 2020 The Trump administration is making moves to replenish the Strategic National Stockpile to get ready for a potential second surge of COVID-19 and will add new supplies like critical care drugs Thursday, May 14, 2020 A new study measuring the performance of Abbott’s rapid, point-of-care coronavirus test found the device could miss nearly half of positive cases, depending on how the samples were handled and fed into the machine. Conducted by researchers at NYU Langone Health, the study was pre-published on bioRxiv, and has not yet been peer-reviewed. Thursday, May 14, 2020 A new study from New York University found that Abbott's point-of-care coronavirus diagnostic could miss nearly half of positive COVID-19 cases. Meanwhile, the FDA is working on a plan to jumpstart on-site drug manufacturing facilities after placing a moratorium on such reviews in early March. Thursday, May 14, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Thursday, May 14, 2020 The BMJ warns that a “deluge of poor quality research [in COVID-19] is sabotaging an effective evidence-based response,” while Nature argues that more patients are needed for better trial results. Thursday, May 14, 2020 Humana has put a focus on its employee well-being initiatives for years—and that work is offering lessons for responding to COVID-19, executives said. Thursday, May 14, 2020 That was fast. Less than a day after Sanofi CEO Paul Hudson said the U.S. would be set for first dibs on the company’s potential COVID-19 vaccine, pushback is mounting, and French President Emmanuel Macron wants a meeting. Thursday, May 14, 2020 In the wake of COVID-19, healthcare providers will need to rethink the traditional waiting room experience. Phoenix-based Banner Health is taking that step with the launch of a virtual waiting room across its Banner Medical Group practices. Thursday, May 14, 2020 The U.S. government's “Operation Warp Speed” aims to deliver a coronavirus vaccine to Americans by the end of the year, drawing on top minds in pharma, government and academia to do it. And now it has an experienced Big Pharma executive leading the charge. Thursday, May 14, 2020 The FDA abruptly shut down its on-site facility inspections in March, hoping to keep its employees safe during the novel coronavirus pandemic. More than two months into that moratorium, drugmakers are calling for relief—and with some new guidance, the FDA shows it might be willing to accommodate. Thursday, May 14, 2020 Providers want the Centers for Medicare & Medicaid Services to extend a deadline for accountable care organizations to decide whether to leave or stay in the program as they struggle to figure out the impact of the pandemic. |  | The need for real-time data in a COVID-19 era. Join Parexel experts during this live webinar as they analyze the role of Real-World Evidence (RWE) and how it supports the urgent need in emerging therapies for COVID-19. Register Now! |
|
|
